C. Harro

发表

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Kenneth H Mayer, K. Mayer, D. Forthal, 2005, The Journal of infectious diseases.

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

Guido Ferrari, Sharon Frey, M Juliana McElrath, 2007, Vaccine.

Enterotoxigenic Escherichia coli–blood group A interactions intensify diarrheal severity

T. Vickers, D. Sack, S. Chakraborty, 2018, The Journal of clinical investigation.

Comparison of mRNA and Protein Measures of Cytokines following Vaccination with Human Papillomavirus-16 L1 Virus-like Particles

R. Lempicki, F. Shebl, A. Hildesheim, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Campylobacter jejuni transcriptional and genetic adaptation during human infection

D. Sack, A. J. McCoy, M. Trent, 2018, Nature Microbiology.

An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli

D. Sack, S. Chakraborty, D. Tribble, 2016, PLoS ONE.

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

D. Mehrotra, J. Shiver, R. Leavitt, 2009, Clinical and Vaccine Immunology.

In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units.

D. Sack, J. Lindow, K. Pierce, 2010, Vaccine.

Rifaximin Fails to Prevent Campylobacteriosis in the Human Challenge Model: A Randomized, Double-Blind, Placebo-Controlled Trial

D. Sack, S. Chakraborty, D. Tribble, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Oral, Live Attenuated Enterotoxigenic Escherichia coli Vaccine ACE527 Reduces the Incidence and Severity of Diarrhea in a Human Challenge Model of Diarrheal Disease

D. Sack, S. Chakraborty, A. L. Bourgeois, 2012, Clinical and Vaccine Immunology.

A Combination Vaccine Consisting of Three Live Attenuated Enterotoxigenic Escherichia coli Strains Expressing a Range of Colonization Factors and Heat-Labile Toxin Subunit B Is Well Tolerated and Immunogenic in a Placebo-Controlled Double-Blind Phase I Trial in Healthy Adults

D. Sack, S. Chakraborty, H. Bloomberg, 2011, Clinical and Vaccine Immunology.

Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response.

G. Drusano, H. Keyserling, C. Harro, 2003, Vaccine.

Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects

D. Sack, S. Chakraborty, L. Dally, 2016, Clinical and Vaccine Immunology.

Safety and Immunogenicity of a Novel Staphylococcus aureus Vaccine: Results from the First Study of the Vaccine Dose Range in Humans

R. Betts, H. Greenberg, W. Orenstein, 2010, Clinical and Vaccine Immunology.

Refinement of a Human Challenge Model for Evaluation of Enterotoxigenic Escherichia coli Vaccines

D. Sack, S. Chakraborty, A. Svennerholm, 2011, Clinical and Vaccine Immunology.

Reﬁnement of a Human Challenge Model for Evaluation of Enterotoxigenic Escherichia coli Vaccines (cid:1)

D. Sack, S. Chakraborty, A. Svennerholm, 2011 .

Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407

D. Sack, S. Chakraborty, A. L. Bourgeois, 2015, Clinical and Vaccine Immunology.

Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers

D. Sack, S. Chakraborty, L. Dally, 2018, PLoS neglected tropical diseases.

Characterization of Mucosal Immune Responses to Enterotoxigenic E. coli

D. Sack, S. Chakraborty, A. L. Bourgeois, 2015 .

HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.

Allan Hildesheim, Philip E Castle, Douglas R Lowy, 2005, Vaccine.

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.

J. Berzofsky, D. Lowy, A. Hildesheim, 2006, Virology.

Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.

J. Berzofsky, D. Lowy, M. Baseler, 2003, The Journal of infectious diseases.

Epitope Enhancement of a CD4 HIV Epitope toward the Development of the Next Generation HIV Vaccine1

Takahiro Okazaki, Pablo Sarobe, J. Berzofsky, 2006, The Journal of Immunology.

Safety and Immunogenicity of a High‐Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV‐1‐Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A

M. Hudgens, D. Montefiori, M. Mulligan, 2002, Journal of acquired immune deficiency syndromes.

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.

S. Self, D. Stablein, S. Buchbinder, 2001, The Journal of infectious diseases.

Interrogation of a live-attenuated enterotoxigenic Escherichia coli vaccine highlights features unique to wild-type infection

Arlo Z. Randall, D. Rasko, T. Vickers, 2019, npj Vaccines.

Human Experimental Challenge With Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine Development

Arlo Z. Randall, D. Rasko, T. Vickers, 2018, The Journal of infectious diseases.

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

R. Karron, B. Murphy, D. Lowy, 2001, Journal of the National Cancer Institute.

Gene Expression Patterns Induced by HPV-16 L1 Virus-Like Particles in Leukocytes from Vaccine Recipients1

L. Dodd, D. Lowy, R. Lempicki, 2009, The Journal of Immunology.

Cytokine and Chemokine Profiles following Vaccination with Human Papillomavirus Type 16 L1 Virus-Like Particles

L. Dodd, D. Lowy, A. Hildesheim, 2007, Clinical and Vaccine Immunology.

Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.

A. Fix, S. Cryz, L. Dally, 2015, Vaccine.

Emerging Issues in Managing Pediatric Parasitic Infections: An Assessment of Clinical and Epidemiological Knowledge of Giardiasis and Cryptosporidiosis

S. Czinn, C. Harro, F. Muñoz, 2015 .

The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies.

R. Betts, N. Kartsonis, C. Harro, 2012, Vaccine.

Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment

M. Pop, H. Bravo, J. Parkhill, 2016, BMC Genomics.

Intestinal and systemic inflammation induced by symptomatic and asymptomatic enterotoxigenic E. coli infection and impact on intestinal colonization and ETEC specific immune responses in an experimental human challenge model

D. Sack, S. Chakraborty, A. L. Bourgeois, 2021, Gut microbes.

Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia coli Infection in Humans.

C. Woods, G. Ginsburg, B. Nicholson, 2016, The Journal of infectious diseases.

Campylobacter jejuni transcriptional and genetic adaptation during human infection

D. Sack, A. J. McCoy, M. Trent, 2018, Nature Microbiology.

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.

J. Kublin, C. del Rio, D. Mehrotra, 2010, The Journal of infectious diseases.

Norovirus vaccine against experimental human Norwalk Virus illness.

D. Graham, D. Bernstein, M. Estes, 2011, The New England journal of medicine.

Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120: Negative Results Fail to Trigger a Phase 3 Correlates Trial

W. Blattner, S. Self, D. Montefiori, 2007, Journal of acquired immune deficiency syndromes.

Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants

Allan C. deCamp, W. Blattner, S. Hammer, 2014, Clinical and Vaccine Immunology.

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.

D. Mehrotra, M. Mulligan, J. Shiver, 2009, AIDS research and human retroviruses.

Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge

D. Sack, S. Chakraborty, A. Fix, 2019, Vaccine.

Recruitment and Baseline Epidemiologic Profile of Participants in the First Phase 3 HIV Vaccine Efficacy Trial

J. Kostman, K. Mayer, B. Bartholow, 2004, Journal of acquired immune deficiency syndromes.

Exploring Changes in the Host Gut Microbiota During a Controlled Human Infection Model for Campylobacter jejuni

D. Sack, B. Stamps, D. Tribble, 2021, Frontiers in Cellular and Infection Microbiology.

Quantitative PCR and culture evaluation for enterotoxigenic Escherichia coli (ETEC) associated diarrhea in volunteers.

D. Sack, S. Chakraborty, B. Lindsay, 2014, FEMS microbiology letters.

HIV Vaccine toward the Development of the Next Generation Epitope Enhancement of a CD4 HIV Epitope

J. Berzofsky, K. Thomas, P. Sarobe, 2012 .

Epitope Enhancement of a CD 4 HIV Epitope toward the Development of the Next Generation HIV Vaccine 1

J. Berzofsky, D. Schwartz, P. Sarobe, 2006 .

Generation HIV Vaccine toward the Development of the Next Epitope Enhancement of a CD4 HIV Epitope

J. Berzofsky, P. Sarobe, C. D. Pendleton, 2006 .

Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.

A. Hildesheim, L. Pinto, C. Harro, 2010, Vaccine.

Interrogation of a live-attenuated enterotoxigenic Escherichia coli vaccine highlights features unique to wild-type infection

Arlo Z. Randall, D. Rasko, T. Vickers, 2019, npj Vaccines.